CD40LG and pachyonychia congenita: There has been a recent report on the potential of this molecule as a predictive biomarker in metastatic PC patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel, observing increased sCD40L concentrations in patients with progressive disease and reduced concentrations in those with a partial response to three months of treatment [29].